Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is one of the few cancers in which a continued increase in incidence has been observed over several years. As such, there has been a focus on safe and accurate diagnosis and the development of treatment algorithms that take into consideration the unique complexities of...
Saved in:
| Published in: | CA: a cancer journal for clinicians Vol. 62; no. 6; pp. 394 - 399 |
|---|---|
| Main Authors: | , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
01.11.2012
Wiley Subscription Services, Inc |
| Subjects: | |
| ISSN: | 0007-9235, 1542-4863, 1542-4863 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Hepatocellular carcinoma (HCC) is one of the few cancers in which a continued increase in incidence has been observed over several years. As such, there has been a focus on safe and accurate diagnosis and the development of treatment algorithms that take into consideration the unique complexities of this patient population. In the past decade, there have been improvements in nonsurgical treatment platforms and better standardization with respect to the diagnosis and patient eligibility for liver transplant. How to navigate patients through the challenges of treatment is difficult and depends on several factors: 1) patient‐related variables such as comorbid conditions that influence treatment eligibility; 2) liver‐related variables such as Child‐Pugh score; and 3) tumor‐related variables such as size, number, pattern of spread within the liver, and vascular involvement. The objectives of this review are to put into perspective the current treatment options for patients with HCC, the unique advantages and disadvantages of each treatment approach, and the evidence that supports the introduction of sorafenib into the multidisciplinary management of HCC. CA Cancer J Clin 2012;. © 2012 American Cancer Society. |
|---|---|
| AbstractList | Hepatocellular carcinoma (HCC) is one of the few cancers in which a continued increase in incidence has been observed over several years. As such, there has been a focus on safe and accurate diagnosis and the development of treatment algorithms that take into consideration the unique complexities of this patient population. In the past decade, there have been improvements in nonsurgical treatment platforms and better standardization with respect to the diagnosis and patient eligibility for liver transplant. How to navigate patients through the challenges of treatment is difficult and depends on several factors: 1) patient‐related variables such as comorbid conditions that influence treatment eligibility; 2) liver‐related variables such as Child‐Pugh score; and 3) tumor‐related variables such as size, number, pattern of spread within the liver, and vascular involvement. The objectives of this review are to put into perspective the current treatment options for patients with HCC, the unique advantages and disadvantages of each treatment approach, and the evidence that supports the introduction of sorafenib into the multidisciplinary management of HCC. CA Cancer J Clin 2012;. © 2012 American Cancer Society. Hepatocellular carcinoma (HCC) is one of the few cancers in which a continued increase in incidence has been observed over several years. As such, there has been a focus on safe and accurate diagnosis and the development of treatment algorithms that take into consideration the unique complexities of this patient population. In the past decade, there have been improvements in nonsurgical treatment platforms and better standardization with respect to the diagnosis and patient eligibility for liver transplant. How to navigate patients through the challenges of treatment is difficult and depends on several factors: 1) patient-related variables such as comorbid conditions that influence treatment eligibility; 2) liver-related variables such as Child-Pugh score; and 3) tumor-related variables such as size, number, pattern of spread within the liver, and vascular involvement. The objectives of this review are to put into perspective the current treatment options for patients with HCC, the unique advantages and disadvantages of each treatment approach, and the evidence that supports the introduction of sorafenib into the multidisciplinary management of HCC.Hepatocellular carcinoma (HCC) is one of the few cancers in which a continued increase in incidence has been observed over several years. As such, there has been a focus on safe and accurate diagnosis and the development of treatment algorithms that take into consideration the unique complexities of this patient population. In the past decade, there have been improvements in nonsurgical treatment platforms and better standardization with respect to the diagnosis and patient eligibility for liver transplant. How to navigate patients through the challenges of treatment is difficult and depends on several factors: 1) patient-related variables such as comorbid conditions that influence treatment eligibility; 2) liver-related variables such as Child-Pugh score; and 3) tumor-related variables such as size, number, pattern of spread within the liver, and vascular involvement. The objectives of this review are to put into perspective the current treatment options for patients with HCC, the unique advantages and disadvantages of each treatment approach, and the evidence that supports the introduction of sorafenib into the multidisciplinary management of HCC. Hepatocellular carcinoma (HCC) is one of the few cancers in which a continued increase in incidence has been observed over several years. As such, there has been a focus on safe and accurate diagnosis and the development of treatment algorithms that take into consideration the unique complexities of this patient population. In the past decade, there have been improvements in nonsurgical treatment platforms and better standardization with respect to the diagnosis and patient eligibility for liver transplant. How to navigate patients through the challenges of treatment is difficult and depends on several factors: 1) patient-related variables such as comorbid conditions that influence treatment eligibility; 2) liver-related variables such as Child-Pugh score; and 3) tumor-related variables such as size, number, pattern of spread within the liver, and vascular involvement. The objectives of this review are to put into perspective the current treatment options for patients with HCC, the unique advantages and disadvantages of each treatment approach, and the evidence that supports the introduction of sorafenib into the multidisciplinary management of HCC. [PUBLICATION ABSTRACT] Hepatocellular carcinoma (HCC) is one of the few cancers in which a continued increase in incidence has been observed over several years. As such, there has been a focus on safe and accurate diagnosis and the development of treatment algorithms that take into consideration the unique complexities of this patient population. In the past decade, there have been improvements in nonsurgical treatment platforms and better standardization with respect to the diagnosis and patient eligibility for liver transplant. How to navigate patients through the challenges of treatment is difficult and depends on several factors: 1) patient-related variables such as comorbid conditions that influence treatment eligibility; 2) liver-related variables such as Child-Pugh score; and 3) tumor-related variables such as size, number, pattern of spread within the liver, and vascular involvement. The objectives of this review are to put into perspective the current treatment options for patients with HCC, the unique advantages and disadvantages of each treatment approach, and the evidence that supports the introduction of sorafenib into the multidisciplinary management of HCC. |
| Author | Covey, Anne Maluccio, Mary |
| Author_xml | – sequence: 1 givenname: Mary surname: Maluccio fullname: Maluccio, Mary email: mmalucci@iupui.edu – sequence: 2 givenname: Anne surname: Covey fullname: Covey, Anne |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23070690$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kd1L5DAUxYO46Pjx4h8gBV9ErOajadLHYfBjQVjY1edym96OkU4yJi0y__2mjvogyz4l9_I7l8M5B2TXeYeEnDB6JQTn1wbAXHHGSrZDZkwWPC90KXbJjFKq8ooLuU8OYnyh06zUHtnngipaVnRG_vxGg27I1sEvA8aYWZeNrsUQB3CtdcvLrLWwdD6-_9MuGwLCkKbsGdcweIN9P_YQMgPBWOdXcER-dNBHPP54D8nT7c3j4j5_-HX3czF_yE0hK5aDaFrksm0USIGaKtE1ynCtFCu6ZLCRTac62RlaQal1ZZpSSW6YFgYalCAOyfn2bjL_OmIc6pWNkx1w6MdYM6YqmfIoyoSefUNf_BhccjdRuhJasypRpx_U2KywrdfBriBs6s-4EnCxBUzwMQbsvhBG66mLeuqifu8iwfQbbOyQkvNuCGD7f0vYVvJme9z853i9mM8XW81fmhybBw |
| CODEN | CAMCAM |
| CitedBy_id | crossref_primary_10_1002_jcp_27095 crossref_primary_10_3389_fonc_2021_681683 crossref_primary_10_3892_ol_2014_1809 crossref_primary_10_4254_wjh_v7_i1_40 crossref_primary_10_1016_j_ultrasmedbio_2019_11_001 crossref_primary_10_1097_TP_0000000000000489 crossref_primary_10_1007_s12032_014_0969_5 crossref_primary_10_2147_OTT_S260556 crossref_primary_10_2174_0929867327666200320153837 crossref_primary_10_1007_s12032_024_02497_0 crossref_primary_10_1016_S1875_5364_18_30027_X crossref_primary_10_1016_j_omtn_2018_08_014 crossref_primary_10_1097_MD_0000000000008144 crossref_primary_10_1038_cddis_2017_411 crossref_primary_10_1080_21691401_2019_1640228 crossref_primary_10_1007_s00432_023_04899_5 crossref_primary_10_1007_s12032_014_0367_z crossref_primary_10_1186_s12885_022_09325_6 crossref_primary_10_2217_nnm_2018_0046 crossref_primary_10_1186_s12951_023_01776_8 crossref_primary_10_1186_s13578_017_0189_8 crossref_primary_10_1080_21655979_2021_1971484 crossref_primary_10_1159_000527800 crossref_primary_10_1016_j_jchromb_2020_122492 crossref_primary_10_1093_carcin_bgy113 crossref_primary_10_1134_S1068162024020043 crossref_primary_10_1136_jitc_2024_008917 crossref_primary_10_4103_0366_6999_159356 crossref_primary_10_1177_1533033820983284 crossref_primary_10_1007_s10620_017_4708_6 crossref_primary_10_1038_srep31298 crossref_primary_10_1016_j_dld_2022_04_009 crossref_primary_10_1016_j_suronc_2020_03_003 crossref_primary_10_1002_hep_29006 crossref_primary_10_1177_03946320231218179 crossref_primary_10_1016_j_bbrc_2017_06_103 crossref_primary_10_3892_ol_2018_9333 crossref_primary_10_1016_j_toxlet_2013_04_018 crossref_primary_10_1016_j_bioorg_2019_102940 crossref_primary_10_1016_j_canlet_2016_03_047 crossref_primary_10_1016_j_yexcr_2018_06_039 crossref_primary_10_1016_j_canlet_2016_09_017 crossref_primary_10_1016_j_ymthe_2017_12_012 crossref_primary_10_3892_ol_2015_3859 crossref_primary_10_1155_2020_2918517 crossref_primary_10_24875_RIC_24000018 crossref_primary_10_1038_s41419_018_0399_y crossref_primary_10_1080_08941939_2021_2021334 crossref_primary_10_1016_j_jhep_2015_03_036 crossref_primary_10_2147_CMAR_S244024 crossref_primary_10_1038_srep33121 crossref_primary_10_1016_j_canlet_2016_11_037 crossref_primary_10_3892_ol_2017_6339 crossref_primary_10_1016_j_canlet_2014_05_001 crossref_primary_10_2147_JHC_S426308 crossref_primary_10_3892_ol_2018_9541 crossref_primary_10_1016_j_bioactmat_2022_01_003 crossref_primary_10_1016_j_biopha_2020_109851 crossref_primary_10_3348_kjr_2016_17_6_882 crossref_primary_10_3390_jpm11030219 crossref_primary_10_1016_j_biomaterials_2017_10_047 crossref_primary_10_1002_mc_23083 crossref_primary_10_1002_tox_24121 crossref_primary_10_1039_C9RA05933D crossref_primary_10_1016_j_ultrasmedbio_2018_09_001 crossref_primary_10_18632_oncotarget_10082 crossref_primary_10_1002_jcp_29595 crossref_primary_10_1371_journal_pone_0077315 crossref_primary_10_3389_fgene_2021_620594 crossref_primary_10_1002_jcp_29596 crossref_primary_10_1186_s12885_018_4996_z crossref_primary_10_1016_j_biopha_2015_04_014 crossref_primary_10_3892_ol_2017_6365 crossref_primary_10_1186_1479_5876_11_273 crossref_primary_10_1097_MD_0000000000007496 crossref_primary_10_1016_j_freeradbiomed_2024_05_043 crossref_primary_10_1186_s12885_017_3633_6 crossref_primary_10_1002_jcb_26883 crossref_primary_10_3892_ol_2017_7688 crossref_primary_10_1038_srep09202 crossref_primary_10_1186_1475_2867_13_27 crossref_primary_10_3389_fonc_2021_713432 crossref_primary_10_1002_adfm_201706600 crossref_primary_10_1080_10717544_2017_1309478 crossref_primary_10_1007_s11684_016_0440_4 crossref_primary_10_1016_j_ejphar_2024_176563 crossref_primary_10_1097_COC_0000000000000724 crossref_primary_10_1186_s12885_019_6489_0 crossref_primary_10_1038_s41419_024_06888_z crossref_primary_10_1016_j_canlet_2015_07_041 crossref_primary_10_1007_s11605_019_04295_w crossref_primary_10_3390_ijms17030320 crossref_primary_10_4254_wjh_v7_i3_362 crossref_primary_10_1093_bib_bbac200 crossref_primary_10_1016_j_ultras_2018_12_006 crossref_primary_10_3390_nano7050111 crossref_primary_10_3748_wjg_v21_i34_9853 crossref_primary_10_1038_emm_2017_166 crossref_primary_10_3748_wjg_v24_i25_2733 crossref_primary_10_1002_ijc_32970 crossref_primary_10_3389_fonc_2021_679336 crossref_primary_10_1155_2020_2357840 crossref_primary_10_1097_RLI_0000000000000137 crossref_primary_10_1111_cpr_12397 crossref_primary_10_4103_ijc_IJC_967_20 crossref_primary_10_1038_srep24582 crossref_primary_10_3748_wjg_v24_i4_484 crossref_primary_10_1002_ijc_30446 crossref_primary_10_3892_mmr_2017_6320 crossref_primary_10_1016_j_livres_2019_11_003 crossref_primary_10_1007_s00464_018_6296_8 crossref_primary_10_3390_ijms241612630 crossref_primary_10_1177_1010428317695031 crossref_primary_10_1016_j_clinre_2017_01_010 crossref_primary_10_1016_j_jconrel_2015_06_013 crossref_primary_10_1186_s12943_017_0675_y crossref_primary_10_1186_s12935_016_0286_5 crossref_primary_10_1186_s12935_021_02298_9 crossref_primary_10_4240_wjgs_v15_i1_19 crossref_primary_10_1186_s12951_022_01389_7 crossref_primary_10_1016_j_hbpd_2019_09_005 crossref_primary_10_1177_1176934320920562 crossref_primary_10_3892_ol_2022_13202 crossref_primary_10_1007_s00261_021_03349_5 crossref_primary_10_1016_j_bbagrm_2016_05_006 crossref_primary_10_1177_1533034618756785 crossref_primary_10_1002_jcb_28989 crossref_primary_10_1016_j_fob_2015_03_010 crossref_primary_10_3389_fonc_2020_01450 crossref_primary_10_1039_D2BM00555G crossref_primary_10_1016_j_ijid_2017_12_002 crossref_primary_10_3892_or_2014_3099 crossref_primary_10_1186_s12935_019_1078_5 crossref_primary_10_3892_ijmm_2014_1800 crossref_primary_10_1089_lap_2017_0479 crossref_primary_10_3892_mco_2015_569 crossref_primary_10_2147_CMAR_S286275 crossref_primary_10_3389_fonc_2023_1088475 crossref_primary_10_1016_j_jss_2016_11_042 crossref_primary_10_1038_s41598_022_14554_7 crossref_primary_10_5582_bst_2019_01289 crossref_primary_10_1016_j_clinre_2016_09_010 crossref_primary_10_1111_cas_14631 crossref_primary_10_1038_s41388_018_0505_8 crossref_primary_10_3892_mmr_2017_6612 crossref_primary_10_1002_stem_1850 crossref_primary_10_1038_s41419_017_0090_8 crossref_primary_10_1007_s13277_014_2023_9 crossref_primary_10_1016_j_canrad_2013_05_016 crossref_primary_10_3389_fonc_2025_1570029 crossref_primary_10_3892_mmr_2017_7820 crossref_primary_10_1002_1878_0261_12846 crossref_primary_10_1186_s12880_024_01258_9 crossref_primary_10_3892_or_2016_5272 crossref_primary_10_1016_j_biomaterials_2018_01_031 crossref_primary_10_2147_CMAR_S245998 crossref_primary_10_1021_acsnano_5c08326 crossref_primary_10_1016_j_nano_2019_102062 crossref_primary_10_1016_j_trac_2020_115965 crossref_primary_10_3748_wjg_v20_i31_10944 crossref_primary_10_4254_wjh_v10_i1_95 crossref_primary_10_1155_2021_5147439 crossref_primary_10_2147_CMAR_S245990 crossref_primary_10_1016_j_jhep_2015_05_005 crossref_primary_10_1111_jcmm_15852 crossref_primary_10_1186_s12964_022_00872_w crossref_primary_10_3892_ol_2018_9263 crossref_primary_10_1097_NCC_0000000000001044 crossref_primary_10_1007_s11605_018_3810_1 crossref_primary_10_1002_stem_2734 crossref_primary_10_1155_2022_6267851 crossref_primary_10_1039_C4TX00227J crossref_primary_10_1186_s13046_019_1433_3 crossref_primary_10_3390_genes15091183 crossref_primary_10_5812_iranjradiol_26009 crossref_primary_10_2217_fon_13_181 crossref_primary_10_1080_21655979_2021_1918538 crossref_primary_10_1002_ijc_30124 crossref_primary_10_1155_2017_2029315 crossref_primary_10_3390_molecules28031293 crossref_primary_10_4103_jcrt_JCRT_629_19 crossref_primary_10_1007_s00394_017_1404_4 crossref_primary_10_1016_j_prp_2018_04_012 crossref_primary_10_3892_mmr_2018_8871 crossref_primary_10_1016_j_cbi_2023_110634 crossref_primary_10_1016_j_cca_2015_06_027 crossref_primary_10_3892_br_2013_197 crossref_primary_10_1111_cas_13200 crossref_primary_10_3892_mmr_2017_6759 crossref_primary_10_1016_j_hbpd_2022_04_001 crossref_primary_10_1002_mc_22954 crossref_primary_10_1016_j_ebiom_2016_07_013 crossref_primary_10_1007_s13277_015_4052_4 crossref_primary_10_1038_ncomms15129 crossref_primary_10_3892_or_2016_5050 crossref_primary_10_3390_jcm10092011 crossref_primary_10_1074_jbc_M116_773978 crossref_primary_10_1155_2022_6304859 crossref_primary_10_1016_j_steroids_2014_03_005 crossref_primary_10_1177_1073274817729240 crossref_primary_10_1016_S1665_2681_19_30846_4 crossref_primary_10_2147_IJN_S470847 crossref_primary_10_1007_s10904_025_03752_1 crossref_primary_10_2217_fvl_14_50 crossref_primary_10_1074_jbc_M114_601203 crossref_primary_10_3892_ijo_2016_3336 crossref_primary_10_1016_j_ijbiomac_2017_05_108 crossref_primary_10_1007_s00261_016_1016_0 crossref_primary_10_1007_s13277_015_4085_8 crossref_primary_10_3748_wjg_v24_i28_3145 crossref_primary_10_3389_fonc_2020_00567 crossref_primary_10_1016_j_canlet_2017_07_031 crossref_primary_10_1016_j_gene_2019_144159 crossref_primary_10_1186_s13244_024_01609_8 crossref_primary_10_1016_j_pdpdt_2024_104446 crossref_primary_10_1002_ijc_32564 crossref_primary_10_1016_j_ultrasmedbio_2020_07_009 crossref_primary_10_1016_j_hbpd_2019_01_003 crossref_primary_10_1007_s11684_017_0546_3 crossref_primary_10_1007_s40137_016_0143_4 crossref_primary_10_1007_s10620_020_06734_0 crossref_primary_10_1055_s_0044_1788691 crossref_primary_10_1245_s10434_016_5107_5 crossref_primary_10_3892_mmr_2019_10471 crossref_primary_10_1109_TUFFC_2018_2874181 crossref_primary_10_1111_jgh_13843 crossref_primary_10_1186_s12885_021_08923_0 crossref_primary_10_1007_s13277_015_4413_z crossref_primary_10_3892_ol_2018_9013 crossref_primary_10_1016_j_ijsu_2017_09_075 crossref_primary_10_1002_ijc_31595 crossref_primary_10_3892_ijmm_2016_2812 crossref_primary_10_1016_S1499_3872_16_60094_2 crossref_primary_10_1080_21655979_2021_1973878 crossref_primary_10_1080_1539445X_2019_1624265 crossref_primary_10_3389_fcell_2022_960277 crossref_primary_10_1016_j_clinre_2019_07_014 crossref_primary_10_1097_MD_0000000000000364 crossref_primary_10_3390_ijms17081373 crossref_primary_10_5500_wjt_v15_i2_98509 crossref_primary_10_1002_adma_201904337 crossref_primary_10_3389_fgene_2022_1000448 crossref_primary_10_1002_tox_24316 crossref_primary_10_1002_jso_23994 crossref_primary_10_3892_ol_2017_6776 crossref_primary_10_1038_s41598_022_16972_z crossref_primary_10_1186_s12876_023_02961_7 crossref_primary_10_1016_j_canlet_2019_01_020 crossref_primary_10_1186_s40658_022_00447_1 crossref_primary_10_3389_fonc_2020_01754 crossref_primary_10_3892_etm_2017_4818 crossref_primary_10_3892_or_2017_5910 crossref_primary_10_1038_s41551_022_00975_2 crossref_primary_10_1055_a_1955_5297 crossref_primary_10_4240_wjgs_v13_i12_1523 crossref_primary_10_1016_j_intimp_2024_112139 crossref_primary_10_1111_jfbc_13122 crossref_primary_10_1039_C8RA07574C crossref_primary_10_1038_s41419_018_0302_x crossref_primary_10_1042_BSR20203945 crossref_primary_10_1097_MD_0000000000021291 crossref_primary_10_3727_096504017X15075967560980 crossref_primary_10_1007_s13577_020_00362_6 crossref_primary_10_3892_ol_2020_11588 crossref_primary_10_1007_s12672_025_02145_7 crossref_primary_10_1038_onc_2016_400 crossref_primary_10_1111_cas_13949 crossref_primary_10_1002_ijc_32599 crossref_primary_10_3390_biomedicines9111527 crossref_primary_10_1016_j_canlet_2017_08_039 crossref_primary_10_1016_j_jhep_2014_05_025 crossref_primary_10_2991_efood_k_200512_001 crossref_primary_10_1016_j_prp_2018_05_002 crossref_primary_10_1002_jcla_24013 crossref_primary_10_1111_febs_14635 crossref_primary_10_1177_1533033820920253 crossref_primary_10_1016_j_jhep_2016_01_019 crossref_primary_10_1371_journal_pone_0095970 crossref_primary_10_5582_bst_8_101 crossref_primary_10_1016_j_hpb_2019_02_003 crossref_primary_10_5582_bst_2016_01176 crossref_primary_10_1016_j_intimp_2022_109581 crossref_primary_10_1111_liv_12898 crossref_primary_10_1016_j_ejpb_2017_04_010 crossref_primary_10_1016_j_ejmech_2018_12_058 crossref_primary_10_1016_j_jconrel_2016_06_009 crossref_primary_10_1177_15330338221150544 crossref_primary_10_1080_15384101_2020_1749471 crossref_primary_10_1002_jcb_26297 crossref_primary_10_1155_2020_7318703 crossref_primary_10_1007_s00210_019_01701_7 crossref_primary_10_1002_jgm_3134 crossref_primary_10_1158_1078_0432_CCR_12_3497 crossref_primary_10_1002_jcp_29832 crossref_primary_10_2147_CMAR_S275307 crossref_primary_10_3892_etm_2017_5421 crossref_primary_10_1016_j_amjms_2017_05_014 crossref_primary_10_1016_j_ijpharm_2020_119334 crossref_primary_10_1080_15384101_2021_1962632 crossref_primary_10_1155_2022_6509028 crossref_primary_10_1007_s13346_024_01780_x crossref_primary_10_1016_j_gene_2018_06_069 crossref_primary_10_3892_or_2016_4815 crossref_primary_10_1177_1010428317709127 crossref_primary_10_1097_CAD_0000000000001053 crossref_primary_10_3389_fonc_2021_650355 crossref_primary_10_1093_jrr_rrt030 crossref_primary_10_2147_OTT_S288791 crossref_primary_10_1038_onc_2014_325 crossref_primary_10_3892_etm_2016_3793 crossref_primary_10_1002_jcp_26779 crossref_primary_10_1080_15548627_2019_1580105 crossref_primary_10_1097_MCG_0000000000001175 crossref_primary_10_1002_biof_1450 crossref_primary_10_1007_s12275_015_5198_x crossref_primary_10_1002_cbdv_202100089 crossref_primary_10_1016_j_biomaterials_2018_07_023 crossref_primary_10_1016_j_humpath_2017_07_008 crossref_primary_10_1016_j_transproceed_2025_02_043 crossref_primary_10_1097_MD_0000000000017552 crossref_primary_10_1002_jcb_27125 crossref_primary_10_1002_jcb_29665 crossref_primary_10_1158_0008_5472_CAN_22_3561 crossref_primary_10_1155_2013_268963 crossref_primary_10_7717_peerj_10307 crossref_primary_10_1096_fj_201800113R crossref_primary_10_1007_s11684_017_0512_0 crossref_primary_10_1016_j_ejso_2021_11_118 crossref_primary_10_1016_j_biopha_2019_108856 crossref_primary_10_3892_or_2014_3248 crossref_primary_10_1093_ajcp_aqac037 crossref_primary_10_1016_j_transproceed_2014_01_011 crossref_primary_10_3389_fonc_2021_755206 crossref_primary_10_2147_DDDT_S231814 crossref_primary_10_1016_j_biopha_2018_07_071 crossref_primary_10_1016_j_clinre_2015_01_006 crossref_primary_10_1097_MD_0000000000024153 crossref_primary_10_1002_slct_202003003 crossref_primary_10_3390_diagnostics11020291 crossref_primary_10_1016_j_prp_2017_12_006 crossref_primary_10_1007_s10620_019_06007_5 crossref_primary_10_1038_s41392_021_00784_0 crossref_primary_10_1016_j_ijpharm_2022_122361 crossref_primary_10_1097_MD_0000000000015682 crossref_primary_10_1097_MD_0000000000012055 crossref_primary_10_1155_2022_7332337 crossref_primary_10_1016_j_canlet_2017_09_049 crossref_primary_10_3892_ol_2017_5826 crossref_primary_10_1038_s41420_021_00710_x crossref_primary_10_3748_wjg_v21_i14_4397 crossref_primary_10_1016_j_omtn_2017_10_018 crossref_primary_10_1016_j_semcancer_2021_06_019 crossref_primary_10_1002_hep_27660 crossref_primary_10_1016_S1499_3872_15_60396_4 crossref_primary_10_1111_cas_14941 crossref_primary_10_3350_cmh_2015_21_2_165 crossref_primary_10_1155_2020_5494858 crossref_primary_10_1186_s12943_017_0733_5 crossref_primary_10_1007_s13277_015_4647_9 crossref_primary_10_1038_s41565_019_0373_6 crossref_primary_10_1016_j_lfs_2017_07_026 crossref_primary_10_3748_wjg_v28_i42_6045 crossref_primary_10_1038_s41418_019_0293_x crossref_primary_10_1002_poh2_41 crossref_primary_10_1016_j_asjsur_2022_07_006 crossref_primary_10_1080_10286020_2018_1490273 crossref_primary_10_1016_j_abb_2018_03_018 crossref_primary_10_1177_0300060516672368 crossref_primary_10_1002_gcc_22120 crossref_primary_10_3346_jkms_2015_30_10_1375 crossref_primary_10_3892_ol_2019_10712 crossref_primary_10_1007_s12094_019_02092_0 crossref_primary_10_1038_s41467_020_18444_2 crossref_primary_10_1007_s00726_021_02966_0 crossref_primary_10_1186_1756_9966_33_32 crossref_primary_10_1155_2018_9289421 crossref_primary_10_3748_wjg_v21_i27_8256 crossref_primary_10_1002_path_4450 crossref_primary_10_1186_s13046_019_1455_x crossref_primary_10_1515_oncologie_2023_0088 crossref_primary_10_1016_j_ultrasmedbio_2017_04_021 crossref_primary_10_1186_s12943_020_01213_6 crossref_primary_10_3892_or_2015_3801 crossref_primary_10_3892_or_2014_3032 crossref_primary_10_1007_s00066_014_0781_3 crossref_primary_10_2147_OTT_S262089 crossref_primary_10_1038_cddis_2016_26 crossref_primary_10_1111_cts_12765 crossref_primary_10_3389_fsurg_2021_675666 crossref_primary_10_1016_j_biomaterials_2016_05_030 crossref_primary_10_1007_s10565_022_09777_3 crossref_primary_10_1111_jgh_12572 crossref_primary_10_1371_journal_pone_0095520 crossref_primary_10_1097_MEG_0000000000000452 crossref_primary_10_3892_ol_2014_1899 crossref_primary_10_1016_j_ultrasmedbio_2016_07_015 crossref_primary_10_3389_fimmu_2023_1076587 crossref_primary_10_1016_j_jhep_2016_02_043 crossref_primary_10_3892_ol_2016_5344 crossref_primary_10_7717_peerj_14303 crossref_primary_10_1038_aps_2017_5 crossref_primary_10_1007_s13337_019_00517_6 crossref_primary_10_1007_s00520_013_2039_5 crossref_primary_10_1155_2021_7430468 crossref_primary_10_5582_bst_2014_01142 crossref_primary_10_3892_ol_2017_6044 crossref_primary_10_1111_cbdd_12866 crossref_primary_10_3892_ol_2017_7131 crossref_primary_10_1007_s11095_019_2669_5 crossref_primary_10_1002_jso_24106 crossref_primary_10_1007_s12072_015_9634_0 crossref_primary_10_3389_fbioe_2023_1135655 crossref_primary_10_1007_s00280_014_2508_7 crossref_primary_10_1002_jbt_21917 crossref_primary_10_1097_MD_0000000000033990 crossref_primary_10_3389_fonc_2021_662408 crossref_primary_10_1186_s12885_021_08431_1 crossref_primary_10_3389_fphys_2018_00321 crossref_primary_10_1002_jcp_28477 crossref_primary_10_1186_s13046_019_1067_5 crossref_primary_10_3892_ol_2014_2727 crossref_primary_10_1016_j_bcp_2018_04_020 crossref_primary_10_1155_2020_7653506 crossref_primary_10_3390_biomedicines11102869 crossref_primary_10_1016_j_nano_2014_07_009 crossref_primary_10_1002_cam4_7165 crossref_primary_10_1016_j_biopha_2020_110111 crossref_primary_10_3892_or_2016_4861 crossref_primary_10_1136_gutjnl_2019_318419 crossref_primary_10_1007_s11596_013_1078_y crossref_primary_10_1016_j_gene_2016_07_031 crossref_primary_10_1038_s42003_021_02071_8 crossref_primary_10_1186_s12929_016_0288_6 crossref_primary_10_1002_jmri_26250 crossref_primary_10_1002_2211_5463_70023 crossref_primary_10_1097_MEG_0000000000001629 crossref_primary_10_1038_s41419_020_03040_5 crossref_primary_10_3748_wjg_v22_i14_3829 crossref_primary_10_1177_1758835920933029 crossref_primary_10_1038_s41419_018_1282_6 crossref_primary_10_1002_cam4_1873 crossref_primary_10_1016_j_canlet_2016_08_011 crossref_primary_10_1097_MD_0000000000020326 crossref_primary_10_1016_j_canlet_2020_06_017 crossref_primary_10_1186_s43046_025_00306_x crossref_primary_10_1002_jcla_23462 crossref_primary_10_1016_j_biomaterials_2013_12_045 crossref_primary_10_1186_s13046_019_1142_y crossref_primary_10_1016_j_canlet_2015_09_020 crossref_primary_10_1186_s13046_019_1188_x crossref_primary_10_1016_j_intimp_2020_106222 crossref_primary_10_3389_fgene_2019_01081 crossref_primary_10_1007_s12253_017_0214_6 crossref_primary_10_1186_s40064_016_3441_5 crossref_primary_10_1155_2019_1684039 crossref_primary_10_1177_08853282231202326 crossref_primary_10_3390_biom9020045 crossref_primary_10_3892_ol_2018_9701 crossref_primary_10_1186_s12967_019_02145_6 crossref_primary_10_1186_s12967_018_1707_0 crossref_primary_10_1371_journal_pone_0085771 crossref_primary_10_1097_MD_0000000000002908 crossref_primary_10_1155_2020_1039312 crossref_primary_10_1007_s00276_019_02396_4 crossref_primary_10_2147_IJN_S308057 crossref_primary_10_3389_fonc_2022_927468 crossref_primary_10_1002_hep_27012 crossref_primary_10_1038_s41598_017_10365_3 crossref_primary_10_1038_s41598_019_39269_0 crossref_primary_10_1186_s12880_015_0058_z crossref_primary_10_1016_j_jep_2018_12_019 crossref_primary_10_1049_iet_nbt_2018_5417 crossref_primary_10_1080_08982104_2019_1570250 crossref_primary_10_1186_1475_2867_13_106 crossref_primary_10_1016_j_canlet_2016_02_053 crossref_primary_10_3389_fphar_2024_1397639 crossref_primary_10_1186_s13046_022_02478_z crossref_primary_10_1177_1010428317694313 crossref_primary_10_1007_s00261_019_02253_3 crossref_primary_10_1002_adfm_202405383 crossref_primary_10_1002_jcp_27449 crossref_primary_10_1038_s41598_022_10972_9 crossref_primary_10_1016_j_bioadv_2023_213309 crossref_primary_10_1186_s12935_022_02479_0 crossref_primary_10_1007_s10989_021_10212_0 crossref_primary_10_1111_cpr_12447 crossref_primary_10_1007_s00261_015_0603_9 crossref_primary_10_1007_s00432_014_1888_8 crossref_primary_10_3389_fimmu_2022_868325 crossref_primary_10_1016_j_cej_2022_138421 crossref_primary_10_1245_s10434_014_3861_9 crossref_primary_10_1371_journal_pone_0062571 crossref_primary_10_1007_s00262_025_04106_z crossref_primary_10_1002_1878_0261_12487 crossref_primary_10_7314_APJCP_2014_15_12_4951 crossref_primary_10_1186_s13046_018_0717_3 crossref_primary_10_1016_j_pathophys_2018_08_008 crossref_primary_10_1038_s41419_024_06711_9 crossref_primary_10_1080_17474124_2017_1343665 crossref_primary_10_1007_s13277_014_2855_3 crossref_primary_10_1038_s41417_022_00540_8 crossref_primary_10_3727_096504017X14876227286564 crossref_primary_10_1111_hepr_13432 crossref_primary_10_1186_s12943_015_0437_7 crossref_primary_10_3892_mmr_2020_10928 crossref_primary_10_2147_JIR_S530061 crossref_primary_10_3389_fbioe_2023_1134665 crossref_primary_10_1002_advs_202205818 crossref_primary_10_1016_j_gene_2016_07_020 crossref_primary_10_1111_jgh_13154 crossref_primary_10_3389_fgene_2021_744113 crossref_primary_10_3389_fgene_2022_892009 crossref_primary_10_1002_smll_202411465 crossref_primary_10_1002_ppsc_201900085 crossref_primary_10_1007_s13369_020_04478_7 crossref_primary_10_1186_s12957_015_0670_y crossref_primary_10_1007_s12032_013_0707_4 crossref_primary_10_1186_s13045_017_0428_9 crossref_primary_10_1002_mp_12717 crossref_primary_10_1002_jso_24297 crossref_primary_10_1007_s13277_015_3060_8 crossref_primary_10_1016_j_ijbiomac_2019_11_122 crossref_primary_10_1155_2022_2021613 crossref_primary_10_1016_j_transproceed_2019_04_026 crossref_primary_10_1097_MD_0000000000018319 crossref_primary_10_1007_s00432_017_2370_1 crossref_primary_10_1016_j_ijpharm_2024_124736 crossref_primary_10_1007_s12094_017_1779_y crossref_primary_10_1038_s41419_018_0681_z crossref_primary_10_1002_jcp_26586 crossref_primary_10_3390_ijms19020327 |
| Cites_doi | 10.1016/j.ejrad.2007.07.007 10.3322/caac.20138 10.1016/S0140-6736(02)08649-X 10.1016/j.ejca.2011.12.021 10.1159/000329040 10.1007/s00534-009-0233-0 10.1055/s-2007-1007122 10.1056/NEJMoa0708857 10.1097/MOT.0b013e3282fc2633 10.1016/j.jhep.2012.01.008 10.1056/NEJM199603143341104 10.1007/s12094-010-0492-x 10.1038/ajg.2011.425 10.1097/01.RVI.0000161377.33557.20 10.1016/j.jhep.2011.03.007 10.1002/cncr.25791 10.1016/S0168-8278(00)80428-6 10.4103/0973-1482.92023 10.1002/hep.510280322 10.1016/j.jvir.2009.12.390 10.1002/cncr.26404 10.1016/j.jvir.2008.02.013 10.1016/S1470-2045(08)70285-7 10.3322/caac.20107 10.1002/hep.24199 10.1053/j.gastro.2010.10.049 10.6004/jnccn.2009.0027 10.1053/j.gastro.2009.09.006 10.1200/JCO.2011.37.1021 10.1016/j.ejca.2011.05.007 10.1016/j.ijrobp.2011.04.011 10.1200/JCO.2005.01.3441 10.1002/cncr.24050 10.3748/wjg.v16.i12.1436 10.1007/s11605-011-1716-2 10.1097/SLA.0b013e318148c704 10.3322/caac.20141 10.1097/01.RVI.0000196277.76812.A3 10.1053/jlts.2002.34892 10.1111/j.1477-2574.2012.00446.x 10.1148/radiol.2241011262 10.1159/000333265 10.1148/radiol.11101840 |
| ContentType | Journal Article |
| Copyright | Copyright © 2012 American Cancer Society, Inc. Copyright Lippincott Williams & Wilkins Nov/Dec 2012 |
| Copyright_xml | – notice: Copyright © 2012 American Cancer Society, Inc. – notice: Copyright Lippincott Williams & Wilkins Nov/Dec 2012 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7T5 7TO 7U9 7X7 7XB 88E 8AO 8FD 8FI 8FJ 8FK 8G5 ABUWG AFKRA AN0 AZQEC BENPR CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ GUQSH H94 K9. KB0 M0S M1P M2O MBDVC NAPCQ P64 PADUT PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS Q9U RC3 7X8 |
| DOI | 10.3322/caac.21161 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Immunology Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Technology Research Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni Edition) ProQuest Central UK/Ireland British Nursing Database ProQuest Central Essentials - QC ProQuest Central ProQuest One Community College ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) Medical Database Research Library Research Library (Corporate) Nursing & Allied Health Premium Biotechnology and BioEngineering Abstracts Research Library China ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic Genetics Abstracts MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student Oncogenes and Growth Factors Abstracts Technology Research Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Central (New) Research Library China ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Central Basic ProQuest One Academic Eastern Edition British Nursing Index with Full Text ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE - Academic Research Library Prep MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: ProQuest Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1542-4863 |
| EndPage | 399 |
| ExternalDocumentID | 2821231581 23070690 10_3322_caac_21161 CAAC21161 |
| Genre | reviewArticle Journal Article Review Feature |
| GroupedDBID | .GA .GJ .Y3 0R~ 10A 18M 1CY 1OB 1OC 23N 24P 2WC 31~ 4.4 41~ 50Y 50Z 51W 51X 52M 52N 52P 52R 52S 52T 52X 53G 5GY 5RE 5VS 66C 6J9 6PF 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAEVG AAFWJ AAONW AAWTL AAZKR ABCQN ABEML ACBNA ACCMX ACGFO ACPRK ACSCC ACXQS ADBBV ADIZJ ADPDF ADXAS AEGXH AEIMD AFBPY AFFNX AFZJQ AHMBA AI. AIAGR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR ATUGU AZBYB BAFTC BAWUL BFHJK BKOMP BY8 C1A CS3 D-6 D-7 D-E D-F DCZOG DIK DR2 E3Z EBD EBS EIHBH EJD EMB EMOBN F00 F01 F04 F5P FAS FJW G-S GODZA GX1 H.X HZ~ IX1 J0M KQ8 L7B LC2 LC3 LH4 LW6 N04 N05 NF~ O66 O9- OHT OK1 OVD OVT P2P P2W P2X P2Z PQQKQ Q.N Q11 QB0 ROL RWL RX1 RXW SJN SUPJJ SV3 TAE TEORI TR2 TWZ UB1 UDS VH1 W2D W8V WH7 WHWMO WIN WOHZO WOQ WQJ WVDHM WXI XG1 XSB XV2 XZL YQJ ZCG ZGI ZVN ZXP ~WT AAYXX CITATION O8X AAHHS ACCFJ ADZOD AEEZP AEQDE AIWBW AJBDE CGR CUY CVF ECM EIF NPM 3V. 7RV 7T5 7TO 7U9 7X7 7XB 88E 8AO 8FD 8FI 8FJ 8FK 8G5 ABUWG AFKRA AN0 AZQEC BENPR CCPQU DWQXO FR3 FYUFA GNUQQ GUQSH H94 K9. M1P M2O MBDVC NAPCQ P64 PADUT PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQUKI PRINS Q9U RC3 7X8 |
| ID | FETCH-LOGICAL-c4591-a3bde25db7a53e8073fb7c287714f307b5bf7f5fc09a6889cb6752c183cabe5a3 |
| IEDL.DBID | 24P |
| ISICitedReferencesCount | 787 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000311270500005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0007-9235 1542-4863 |
| IngestDate | Thu Sep 04 17:45:27 EDT 2025 Thu Oct 02 22:16:17 EDT 2025 Thu Apr 03 06:57:06 EDT 2025 Sat Nov 29 06:54:26 EST 2025 Tue Nov 18 21:45:36 EST 2025 Sun Sep 21 06:15:19 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Language | English |
| License | http://onlinelibrary.wiley.com/termsAndConditions#vor Copyright © 2012 American Cancer Society, Inc. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4591-a3bde25db7a53e8073fb7c287714f307b5bf7f5fc09a6889cb6752c183cabe5a3 |
| Notes | The authors report no conflicts of interest. DISCLOSURES SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.3322/caac.21161 |
| PMID | 23070690 |
| PQID | 1178938819 |
| PQPubID | 6515 |
| PageCount | 6 |
| ParticipantIDs | proquest_miscellaneous_1179515446 proquest_journals_1178938819 pubmed_primary_23070690 crossref_primary_10_3322_caac_21161 crossref_citationtrail_10_3322_caac_21161 wiley_primary_10_3322_caac_21161_CAAC21161 |
| PublicationCentury | 2000 |
| PublicationDate | November/December 2012 |
| PublicationDateYYYYMMDD | 2012-11-01 |
| PublicationDate_xml | – month: 11 year: 2012 text: November/December 2012 |
| PublicationDecade | 2010 |
| PublicationPlace | Hoboken |
| PublicationPlace_xml | – name: Hoboken – name: United States – name: Atlanta |
| PublicationTitle | CA: a cancer journal for clinicians |
| PublicationTitleAlternate | CA Cancer J Clin |
| PublicationYear | 2012 |
| Publisher | Wiley Subscription Services, Inc., A Wiley Company Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc., A Wiley Company – name: Wiley Subscription Services, Inc |
| References | 2007; 246 2010; 12 1998; 28 2010; 16 2011; 117 2011; 80 2010; 17 2011; 81 2008; 19 2006; 17 2011; 61 2002; 8 2011; 53 2002; 359 2011; 55 2008; 13 2011; 15 2012; 14 2012; 56 2012; 107 2011; 7 2009; 115 2010; 21 2009; 10 2006; 24 1999; 19 2010; 138 2000; 32 2002; 224 2008; 67 2008; 359 2009; 7 2012; 48 2011; 47 2011; 261 1996; 334 2011; 140 2005; 16 2011; 29 2012; 118 2010; 9 2012; 62 e_1_2_9_30_2 e_1_2_9_10_2 e_1_2_9_33_2 e_1_2_9_12_2 e_1_2_9_31_2 Lo SS (e_1_2_9_34_2) 2010; 9 e_1_2_9_11_2 e_1_2_9_32_2 e_1_2_9_14_2 e_1_2_9_37_2 e_1_2_9_13_2 e_1_2_9_38_2 e_1_2_9_16_2 e_1_2_9_35_2 e_1_2_9_15_2 e_1_2_9_36_2 e_1_2_9_18_2 e_1_2_9_17_2 e_1_2_9_39_2 e_1_2_9_19_2 e_1_2_9_40_2 e_1_2_9_41_2 e_1_2_9_21_2 e_1_2_9_44_2 e_1_2_9_20_2 e_1_2_9_45_2 e_1_2_9_23_2 e_1_2_9_42_2 Schlesinger S (e_1_2_9_6_2) e_1_2_9_22_2 e_1_2_9_43_2 e_1_2_9_7_2 e_1_2_9_5_2 e_1_2_9_4_2 e_1_2_9_3_2 e_1_2_9_2_2 e_1_2_9_9_2 e_1_2_9_8_2 e_1_2_9_25_2 e_1_2_9_24_2 e_1_2_9_27_2 e_1_2_9_46_2 e_1_2_9_26_2 e_1_2_9_29_2 e_1_2_9_28_2 |
| References_xml | – volume: 138 start-page: 52 year: 2010 end-page: 64 article-title: Radioembolization for hepatocellular carcinoma using Yttrium‐90 microspheres: a comprehensive report of long‐term outcomes publication-title: Gastroenterology. – volume: 334 start-page: 693 year: 1996 end-page: 699 article-title: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis publication-title: N Engl J Med. – volume: 24 start-page: 4293 year: 2006 end-page: 4300 article-title: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma publication-title: J Clin Oncol. – volume: 16 start-page: 1436 year: 2010 end-page: 1441 article-title: Nonalcoholic steatohepatitis‐associated hepatocellular carcinoma: our case series and literature review publication-title: World J Gastroenterol. – volume: 107 start-page: 569 year: 2012 end-page: 577 article-title: Radiofrequency ablation for hepatocellular carcinoma: 10‐year outcome and prognostic factors publication-title: Am J Gastroenterol. – volume: 19 start-page: 862 year: 2008 end-page: 869 article-title: Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma publication-title: J Vasc Interv Radiol. – volume: 224 start-page: 47 year: 2002 end-page: 54 article-title: Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta‐analysis of randomized controlled trials publication-title: Radiology. – volume: 17 start-page: 217 issue: 2 Pt 1 year: 2006 end-page: 223 article-title: Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies publication-title: J Vasc Interv Radiol. – volume: 67 start-page: 336 year: 2008 end-page: 347 article-title: Radiofrequency ablation of hepatocellular carcinoma: long‐term outcome and prognostic factors publication-title: Eur J Radiol. – volume: 32 start-page: 225 issue: suppl 1 year: 2000 end-page: 237 article-title: Hepatocellular carcinoma publication-title: J Hepatol. – volume: 7 start-page: 350 year: 2009 end-page: 391 article-title: NCCN clinical practice guidelines in oncology: hepatobiliary cancers publication-title: J Natl Compr Canc Netw. – volume: 62 start-page: 10 year: 2012 end-page: 29 article-title: Cancer statistics, 2012 publication-title: CA Cancer J Clin. – volume: 81 start-page: 73 issue: suppl 1 year: 2011 end-page: 85 article-title: Diagnostic imaging of hepatocellular carcinoma: recent progress publication-title: Oncology. – volume: 53 start-page: 1020 year: 2011 end-page: 1022 article-title: Management of hepatocellular carcinoma: an update publication-title: Hepatology. – volume: 7 start-page: 463 year: 2011 end-page: 475 article-title: An overview of evidence‐based management of hepatocellular carcinoma: a meta‐analysis publication-title: J Cancer Res Ther. – volume: 14 start-page: 285 year: 2012 end-page: 290 article-title: Systematic review of actual 10‐year survival following resection for hepatocellular carcinoma publication-title: HPB (Oxford). – volume: 16 start-page: 955 year: 2005 end-page: 961 article-title: Comparison of survival rates after bland arterial embolization and ablation versus surgical resection for treating solitary hepatocellular carcinoma up to 7 cm publication-title: J Vasc Interv Radiol. – volume: 29 start-page: 3960 year: 2011 end-page: 3967 article-title: Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug‐eluting beads for hepatocellular carcinoma publication-title: J Clin Oncol. – volume: 261 start-page: 834 year: 2011 article-title: Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid‐enchanced MR imaging publication-title: Radiology. – volume: 115 start-page: 616 year: 2009 end-page: 623 article-title: Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? publication-title: Cancer. – volume: 9 start-page: 404 year: 2010 end-page: 410 article-title: Stereotactic body radiation therapy for hepatocellular carcinoma publication-title: Discov Med. – volume: 117 start-page: 2478 year: 2011 end-page: 2488 article-title: V‐CLIP: integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials publication-title: Cancer. – volume: 80 start-page: 373 year: 2011 end-page: 381 article-title: I‐CLIP: improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IFG‐1 into CLIP score publication-title: Oncology. – volume: 19 start-page: 329 year: 1999 end-page: 338 article-title: Prognosis of hepatocellular carcinoma: the BCLC staging classification publication-title: Semin Liver Dis. – volume: 55 start-page: 1309 year: 2011 end-page: 1316 article-title: EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization publication-title: J Hepatol. – volume: 62 start-page: 118 year: 2012 end-page: 128 article-title: Cancers with increasing incidence trends in the United States: 1999 through 2008 publication-title: CA Cancer J Clin. – article-title: Abdominal obesity, weight gain during adulthood and risk of liver and biliary tract cancer in a European cohort [published online ahead of print May 23, 2012] publication-title: Int J Cancer. – volume: 47 start-page: 2117 year: 2011 end-page: 2127 article-title: Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma publication-title: Eur J Cancer. – volume: 140 start-page: 497 year: 2011 end-page: 507.e2 article-title: Radioembolization results in longer time‐to‐progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma publication-title: Gastroenterology. – volume: 10 start-page: 25 year: 2009 end-page: 34 article-title: Efficacy and safety of sorafenib in patients in the Asia‐Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double‐blind, placebo‐controlled trial publication-title: Lancet Oncol. – volume: 61 start-page: 69 year: 2011 end-page: 90 article-title: Global cancer statistics publication-title: CA Cancer J Clin. – volume: 359 start-page: 378 year: 2008 end-page: 390 article-title: Sorafenib in advanced hepatocellular carcinoma publication-title: N Engl J Med. – volume: 21 start-page: 522 year: 2010 end-page: 526 article-title: Arterial patency after repeated hepatic artery bland particle embolization publication-title: J Vasc Interv Radiol. – volume: 359 start-page: 1734 year: 2002 end-page: 1739 article-title: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial publication-title: Lancet. – volume: 15 start-page: 2165 year: 2011 end-page: 2171 article-title: Long‐term outcome of percutaneous ablation in very early‐stage hepatocellular carcinoma publication-title: J Gastrointest Surg. – volume: 28 start-page: 751 year: 1998 end-page: 755 article-title: A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators publication-title: Hepatology. – volume: 56 start-page: 1330 year: 2012 end-page: 1335 article-title: Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design publication-title: J Hepatol. – volume: 13 start-page: 234 year: 2008 end-page: 240 article-title: Current approach to down‐staging of hepatocellular carcinoma prior to liver transplantation publication-title: Curr Opin Organ Transplant. – volume: 12 start-page: 218 year: 2010 end-page: 225 article-title: Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma publication-title: Clin Transl Oncol. – volume: 48 start-page: 599 year: 2012 end-page: 641 article-title: EASL‐EORTC clinical practice guidelines: management of hepatocellular carcinoma publication-title: Eur J Cancer. – volume: 118 start-page: 3191 year: 2012 end-page: 3198 article-title: Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma publication-title: Cancer. – volume: 17 start-page: 399 year: 2010 end-page: 403 article-title: Hepatocellular carcinoma: new options for image‐guided ablation publication-title: J Hepatobiliary Pancreat Sci. – volume: 8 start-page: 765 year: 2002 end-page: 774 article-title: Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria publication-title: Liver Transpl. – volume: 246 start-page: 502 year: 2007 end-page: 509 article-title: Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22‐year experience with 467 patients at UCLA publication-title: Ann Surg. – volume: 81 start-page: e447 year: 2011 end-page: e453 article-title: Stereotactic body radiotherapy for primary hepatocellular carcinoma publication-title: Int J Radiat Oncol Biol Phys. – volume: 9 start-page: 404 year: 2010 ident: e_1_2_9_34_2 article-title: Stereotactic body radiation therapy for hepatocellular carcinoma publication-title: Discov Med. – ident: e_1_2_9_37_2 doi: 10.1016/j.ejrad.2007.07.007 – ident: e_1_2_9_3_2 doi: 10.3322/caac.20138 – ident: e_1_2_9_25_2 doi: 10.1016/S0140-6736(02)08649-X – ident: e_1_2_9_9_2 doi: 10.1016/j.ejca.2011.12.021 – ident: e_1_2_9_15_2 doi: 10.1159/000329040 – ident: e_1_2_9_39_2 doi: 10.1007/s00534-009-0233-0 – ident: e_1_2_9_13_2 doi: 10.1055/s-2007-1007122 – ident: e_1_2_9_43_2 doi: 10.1056/NEJMoa0708857 – ident: e_1_2_9_19_2 doi: 10.1097/MOT.0b013e3282fc2633 – ident: e_1_2_9_29_2 doi: 10.1016/j.jhep.2012.01.008 – ident: e_1_2_9_16_2 doi: 10.1056/NEJM199603143341104 – ident: e_1_2_9_33_2 doi: 10.1007/s12094-010-0492-x – ident: e_1_2_9_40_2 doi: 10.1038/ajg.2011.425 – ident: e_1_2_9_38_2 doi: 10.1097/01.RVI.0000161377.33557.20 – ident: e_1_2_9_32_2 doi: 10.1016/j.jhep.2011.03.007 – ident: e_1_2_9_14_2 doi: 10.1002/cncr.25791 – ident: e_1_2_9_5_2 doi: 10.1016/S0168-8278(00)80428-6 – ident: e_1_2_9_20_2 doi: 10.4103/0973-1482.92023 – ident: e_1_2_9_12_2 doi: 10.1002/hep.510280322 – ident: e_1_2_9_24_2 doi: 10.1016/j.jvir.2009.12.390 – ident: e_1_2_9_36_2 doi: 10.1002/cncr.26404 – ident: e_1_2_9_23_2 doi: 10.1016/j.jvir.2008.02.013 – ident: e_1_2_9_44_2 doi: 10.1016/S1470-2045(08)70285-7 – ident: e_1_2_9_2_2 doi: 10.3322/caac.20107 – ident: e_1_2_9_6_2 article-title: Abdominal obesity, weight gain during adulthood and risk of liver and biliary tract cancer in a European cohort [published online ahead of print May 23, 2012] publication-title: Int J Cancer. – ident: e_1_2_9_7_2 doi: 10.1002/hep.24199 – ident: e_1_2_9_30_2 doi: 10.1053/j.gastro.2010.10.049 – ident: e_1_2_9_8_2 doi: 10.6004/jnccn.2009.0027 – ident: e_1_2_9_31_2 doi: 10.1053/j.gastro.2009.09.006 – ident: e_1_2_9_45_2 doi: 10.1200/JCO.2011.37.1021 – ident: e_1_2_9_46_2 doi: 10.1016/j.ejca.2011.05.007 – ident: e_1_2_9_35_2 doi: 10.1016/j.ijrobp.2011.04.011 – ident: e_1_2_9_42_2 doi: 10.1200/JCO.2005.01.3441 – ident: e_1_2_9_28_2 doi: 10.1002/cncr.24050 – ident: e_1_2_9_22_2 doi: 10.3748/wjg.v16.i12.1436 – ident: e_1_2_9_41_2 doi: 10.1007/s11605-011-1716-2 – ident: e_1_2_9_18_2 doi: 10.1097/SLA.0b013e318148c704 – ident: e_1_2_9_4_2 doi: 10.3322/caac.20141 – ident: e_1_2_9_27_2 doi: 10.1097/01.RVI.0000196277.76812.A3 – ident: e_1_2_9_17_2 doi: 10.1053/jlts.2002.34892 – ident: e_1_2_9_21_2 doi: 10.1111/j.1477-2574.2012.00446.x – ident: e_1_2_9_26_2 doi: 10.1148/radiol.2241011262 – ident: e_1_2_9_11_2 doi: 10.1159/000333265 – ident: e_1_2_9_10_2 doi: 10.1148/radiol.11101840 |
| SSID | ssj0000777 |
| Score | 2.595106 |
| SecondaryResourceType | review_article |
| Snippet | Hepatocellular carcinoma (HCC) is one of the few cancers in which a continued increase in incidence has been observed over several years. As such, there has... |
| SourceID | proquest pubmed crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 394 |
| SubjectTerms | Ablation Techniques Algorithms Benzenesulfonates - therapeutic use Cancer Carcinoma, Hepatocellular - diagnosis Carcinoma, Hepatocellular - therapy Chemoembolization, Therapeutic decision‐making/patient preferences Embolization, Therapeutic - methods Humans liver neoplasms Liver Neoplasms - diagnosis Liver Neoplasms - therapy Liver Transplantation Medical diagnosis Medical treatment Niacinamide - analogs & derivatives Phenylurea Compounds Protein Kinase Inhibitors - therapeutic use Pyridines - therapeutic use Radiosurgery |
| SummonAdditionalLinks | – databaseName: Nursing & Allied Health Database dbid: 7RV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JSywxEC7ckHdx9712I6IXxTDT051O-iTDoHhQETe8NVlR0G6fM-Pvt5LuGRXFi7deAgmpSn1fJZUqgF0ERekSJalhzNFU5Yoqk0uaMi1cO-FChVx6t6f8_Fzc3eUXzYZbvwmrHNnEYKhNpf0eeSuOOUKrQAA7fP5PfdUof7ralNCYhOnYc2PUZ355-26JOa9zZrY5RSLD6vSkCepwS0scLjo_WfwZkL6wzM-kNaDO8fxvx7sAcw3fJN1aQRZhwpZLMHvWnKgvwxXyRsQdEuK00OqRh5IMP154OSCmjsYLz_iNhNh0fCP3CGWDym_9-1hWon1ZorJ6kitwc3x03TuhTaEFqlOWx1QmytgOM4pLlliBq94prtGX4nHq0Agophx3zOl2LjMhcq3QzehotAZaKstksgpTZVXaf0Ayq4VIDdJAi1zBGpFxh6zOZcJoHecmgr3RbBe6yULui2E8FuiNeMkUXjJFkEwEO-O2z3XujW9bbYwEUDTrr1-8z34E2-PfuHL8nMjSVsPQBuklQ384gr-1sMfd-PB4n8M5gv0g_R_6L3rdbi88rf08knX4g2yrU19k3ICpwcvQbsKMfh089F-2gua-AV5i9jc priority: 102 providerName: ProQuest |
| Title | Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.3322%2Fcaac.21161 https://www.ncbi.nlm.nih.gov/pubmed/23070690 https://www.proquest.com/docview/1178938819 https://www.proquest.com/docview/1179515446 |
| Volume | 62 |
| WOSCitedRecordID | wos000311270500005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library Free Content customDbUrl: eissn: 1542-4863 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000777 issn: 0007-9235 databaseCode: WIN dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library Open Access customDbUrl: eissn: 1542-4863 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000777 issn: 0007-9235 databaseCode: 24P dateStart: 19970101 isFulltext: true titleUrlDefault: https://authorservices.wiley.com/open-science/open-access/browse-journals.html providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1ZS8QwEB5ERXzxPupFRF8Ui9sjmxR8WRdFQdfFc99KThS0K7rr73eSdldFEcSXkLQJKZPMzDfpZAZgG5WisIkUoabUhqnMZCh1JsKUKm5rCePSx9K7PWOtFu90svYIHAzuwpTxIYYHbo4zvLx2DC6kz0KS4B7ERVQCJ0Tzxdk-Y1GUMLen47T9IYcZKyNm1liIMIaWwUnd6P2PsV_V0TeM-RWyep1zPP2_r52BqQprkka5OWZhxBRzMHFe_U2fhyvEjKhziPfRQolHHgrS_3zZZY_o0hPP1_EZ8X7p2CL3qMZ6XXfs7_xYiXIpiYruk1iAm-Oj6-ZJWCVZCFVKsygUidQmployQRPDkeOtZArtKBalFgWApNIyS62qZaLOeaYkmhixQkmghDRUJIswWnQLswykbhTnqUYIaBAnGM3rzCKis3WulYoyHcDOgNa5qiKQu0QYjzlaIo5OuaNS7qkUwNaw73MZd-PHXmuDJcsr3nt14csRhHGEOgFsDl8j1ziaiMJ0-74PQkuKtnAAS-VSD6dxrvEufnMAu35Ff5k_bzYaTV9b-UvnVZhE3BWXVxrXYLT30jfrMK7eeg-vLxt-F2PJLm9d2WG-5BswdnjUal9i6zy-wPLutPUOcnz6gg |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VgoBLeRUILWAEHEC1unk4dg5VtVqoWnW7QqKgvQU_RaU2abu7Rf1T_EbGTrJtBeqtB25OYuXh-TzzTTyeAXiHRlG6VElqGHM0U4WiyhSSZkwL10u5UCGX3vchH43EeFx8WYDf3V4YH1bZ6cSgqE2t_T_y9TjmaFoFGrDN4xPqq0b51dWuhEYDi117_gtdtsnGzieU7_sk2fq8P9imbVUBqjNWxFSmytiEGcUlS61AiDvFNToOPM4cIl4x5bhjTvcKmQtRaIWcOtEIfS2VZTLF-96C26jHuXf2-JhfaH7OmxydPU6ROLEmHWqKc2ZdSxwedLby-KoB_IvVXiXJwcptPfjfxuchLLV8mvSbCfAIFmz1GO7utREDT-Ar8mK0qyTEoaFWJwcVmV3e0LNGTBNtGNp4joTYezwiP9FUT2u_tOFjdYn2ZZeq-kguw7cb-aSnsFjVlX0OJLdaiMwgzbXIhawROXfIWl0ujNZxYSL40Em31G2WdV_s47BEb8sjofRIKAMSIng773vc5Bb5Z6_VTuBlq18m5YW0I3gzv4yawY-JrGw9C32QPjP09yN41oBr_hgf_u9zVEfwMaDtmueXg35_EFovrn-T13Bve39vWA53RrsrcB-ZZdJs2lyFxenpzL6EO_psejA5fRVmDYEfNw3DPyN-U8g |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3da9swED9GO8Je1n1185puGuvLSk2T2LLkx5AtrDQLgbUlb0afrNDaIU329_dOdpOFlkLZmz9OyJx0d7-TTz8BHGBQVD7RKrac-zjVuY61zVWcciN9JxFSBy69i5EYj-V0mk-a2hzaC1PzQ6wW3Mgygr8mA3cz68nKE5yEOIpGYY-Yv1Dys51ydLJE7JxO1o5YiJoysyNixDG8Ziel1sfrtpvx6B7I3MSsIegMd_7zc1_BywZtsn49PV7DM1e-gdav5n_6W_iNqBGjDgtVWujz2GXJlv9udzlitq7FC9f4jIXKdLxjfzCQLSpa-KdKVmboUKKyulbv4Hz442zwM26OWYhNyvNurBJtXY9bLRRPnESb91oYzKREN_XoAjTXXnjuTSdXmZS50Zhk9Az6AqO04yrZha2yKt0HYJkzUqYWQaBDpOCszIRHTOczaY3p5jaCb3fKLkzDQU5HYVwVmIuQngrSUhG0FMHXleysZt54UKp9N2ZFY303RGCOMEwi2Ingy-o12g3pRJWuWgYZBJccs-EI3tdjveqGiuOJwTmCwzCkj_RfDPr9Qbj6-BThz9CafB8Wo5Px6R68QBDWq_c3tmFrMV-6fXhu_i4ub-afwoy-BezO94E |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Recent+progress+in+understanding%2C+diagnosing%2C+and+treating+hepatocellular+carcinoma&rft.jtitle=CA%3A+a+cancer+journal+for+clinicians&rft.au=Maluccio%2C+Mary&rft.au=Covey%2C+Anne&rft.date=2012-11-01&rft.issn=1542-4863&rft.eissn=1542-4863&rft.volume=62&rft.issue=6&rft.spage=394&rft_id=info:doi/10.3322%2Fcaac.21161&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-9235&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-9235&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-9235&client=summon |